Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
10 stocks that are pushing the Nasdaq to 5,000
Biotech and medical-device companies are leading the charge, with gains up to 265%, writes Phil van Doorn. 
Tags Medical Products Telecommunications NLST
From MarketWatch
Taglich Brothers Initiates Coverage on Apricus Biosciences, Inc.
From Marketwired News Releases
Taglich Brothers Initiates Coverage with Speculative Buy Recommendation on Apricus Biosciences - Video Research Alert on InvestmentPitch.com
From Newsfile Corp News Releases
Apricus Biosciences Announces $11 Million Registered Direct Offering With Sarissa Capital Management LP
From GlobeNewswire News Releases
Apricus Biosciences Expands Exclusive License Agreement With an Existing Partner to Market Vitaros(R) in Select Asia-Pacific Countries
Apricus Eligible to Receive an Additional Upfront, Milestone Payment and a Double-Digit Royalty on Net Sales 
From GlobeNewswire News Releases
Apricus Biosciences to Present at the 17th Annual BIO CEO & Investor Conference
From GlobeNewswire News Releases
Morning Market Gainers
ABIOMED, Inc. (NASDAQ: ABMD) shares jumped 34.96% to $52.13 after the company reported upbeat quarterly results and raised its ... 
Tags X BABA Movers
From Benzinga
Wednesday Morning Movers: Apple Climbing Following Record-Breaking Earnings
Apricus Biosciences Inc(NASDAQ: APRI) +21% - Announces issuance of U.S. patents for Rayva. Apple Inc. (NASDAQ: AAPL) +8% - ... 
Tags ACAT SSRI HES
From Benzinga
Apricus Biosciences Announces Issuance of U.S. Patent for RayVa(TM)
From GlobeNewswire News Releases
Apricus Biosciences Announces the Appointment of Catherine Bovenizer as Vice President of Finance, Chief Accounting Officer
From GlobeNewswire News Releases
Building Value: Apricus Biosciences Report Issued by BrokerBank Securities, Inc.
From PR Newswire
Apricus Biosciences to Present at Biotech Showcase 2015
From GlobeNewswire News Releases
Apricus Biosciences Offers Year-End '14 Update; in '15 Plans to Advance Clinical Pipeline, Further Commercialization of ED Drug Vitaros(R)
Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, ... 
Tags APRI Benzinga News
From Benzinga
Apricus Biosciences Announces Year-End 2014 Update and 2015 Plans to Advance Its Clinical Pipeline and Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)
From GlobeNewswire News Releases
Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer
Company Also Announces Additional Senior Management Change 
From GlobeNewswire News Releases
APRI Announces First Patient Enrolled In Phase 2a Trial For RayVa; Keryx Announces Issuance Of New U.S. Patent For Auryxia
A look at some of the headlines for companies that made news in the healthcare sector on December 4, 2014, including APRI, KERX, ALDX, CCXI 
Tags Pharma/Biotech Stocks / Equities Healthcare
From Blogs - TalkMarkets
Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in Patients With Raynaud's Phenomenon
From GlobeNewswire News Releases
Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer
Company Also Announces Management Changes 
From GlobeNewswire News Releases
Apricus Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Apricus Biosciences to Present at Three Upcoming Investor Conferences in November and December of 2014
All Presentations Will be Available Via Webcast 
From GlobeNewswire News Releases
Apricus Biosciences Announces Corporate Update and Third Quarter 2014 Financial Results Conference Call
Conference Call and Webcast to be Held Monday, November 10, 2014 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Belgium by Sandoz
To Be Commercialized in Belgium as Vytaros(R), Following Successful Launches in the United Kingdom, Sweden and Germany as Vitaros(R) Earlier This Year 
From GlobeNewswire News Releases
Morning Market Movers
SinoCoking Coal and Coke Chemical Industries (NASDAQ: SCOK) shares jumped 43.66% to $3.38 as aboveground syngas facility commenced ... 
Tags SHOR Movers ACTG
From Benzinga
Apricus Expands Development Pipeline With the In-Licensing of U.S. Rights for Fispemifene, a Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions in Men
From GlobeNewswire News Releases
Morning Market Losers
ALCO Stores (NYSE: ALCS) shares slipped 72.48% to $0.45 after the company filed for voluntary Chapter 11 bankruptcy. Aerohive ... 
Tags ALCS HIVE SFLY
From Benzinga
Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa(TM)
From GlobeNewswire News Releases
Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
From GlobeNewswire News Releases
Apricus CEO to Discuss Company's Drug Portfolio, Including Its Topical Cream for Erectile Dysfunction, Vitaros(R), LIVE on iHeart (Clear Channel) Business Talk Radio DFW 1190AM on Sept. 25, 2014
Interview to Air at 7:30am EDT / 4:30am PDT / 6:30am CDT on the Traders Network Radio Show, Hosted by Michael Yorba 
From Marketwired News Releases
Apricus Biosciences to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
From GlobeNewswire News Releases
Apricus Biosciences Announces the Launch of Its Topical Treatment for Erectile Dysfunction Vitaros(R) in Germany by Hexal
Apricus Continues With Its Series of Ex-US Vitaros(R) Launches Expected Throughout 2014 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.